Evaluations โบ Florida AHCA ยท Last reviewed 2026-05-16
Florida AHCA review (2022)
Summary
The Florida Agency for Health Care Administration (AHCA) issued a report on 2 June 2022, signed by the state Medicaid director, concluding that puberty blockers, hormone therapy and sex-reassignment surgery are "experimental and investigational" and not consistent with generally accepted professional medical standards for the purposes of Medicaid. AHCA announced that it would start rulemaking (source).
1. Commission and methodology
The report โ titled Florida Medicaid: Generally Accepted Professional Medical Standards Determination on the Treatment of Gender Dysphoria โ reviewed literature, clinical guidelines and the coverage decisions of other insurers and countries, and found that research supports these treatments too weakly to show that they are effective and safe (source).1
2. Policy consequences
- AHCA announced rulemaking to exclude these treatments from Medicaid coverage (June 2022) (source).
- On 28 October 2022 the Florida Board of Medicine voted to start drafting a rule that would bar minors from puberty blockers, hormone therapy and surgery for gender dysphoria (source).
- Law SB 254, approved by the governor on 17 May 2023, prohibits sex-reassignment prescriptions and procedures for patients younger than 18 (source).
See also
- Clinical context in the US: United States โ Endocrine Society, AAP, WPATH
- Subsequent legal case: US v Skrmetti
- Comparable evidence-based reviews: Cass Review, SBU 2022
- People register โ Florida figures and authors involved.
- International comparison โ policy in table form.
- Timeline 2022 โ position in chronology.
- FAQ ยท Glossary ยท For clinicians.
Footnotes
- Florida Agency for Health Care Administration. Florida Medicaid: Generally Accepted Professional Medical Standards Determination on the Treatment of Gender Dysphoria. June 2022.